239 related articles for article (PubMed ID: 34436049)
1. CRISPR/Cas12a-Based Ultrasensitive and Rapid Detection of
Chen M; Zhang C; Hu Z; Li Z; Li M; Wu L; Zhou M; Liang D
Biosensors (Basel); 2021 Jul; 11(8):. PubMed ID: 34436049
[TBL] [Abstract][Full Text] [Related]
2. Rapid identification of heterozygous or homozygous JAK2(V617F) mutations in myeloproliferative neoplasms using melting curve analysis.
Ho CL; Wu YY; Hung HM; Chang PY; Kao WY; Chen YC; Chao TY
J Formos Med Assoc; 2012 Jan; 111(1):34-40. PubMed ID: 22333011
[TBL] [Abstract][Full Text] [Related]
3. Design and evaluation of a real-time PCR assay for quantification of JAK2 V617F and wild-type JAK2 transcript levels in the clinical laboratory.
Merker JD; Jones CD; Oh ST; Schrijver I; Gotlib J; Zehnder JL
J Mol Diagn; 2010 Jan; 12(1):58-64. PubMed ID: 19959796
[TBL] [Abstract][Full Text] [Related]
4. Molecular diagnosis of the myeloproliferative neoplasms: UK guidelines for the detection of JAK2 V617F and other relevant mutations.
Bench AJ; White HE; Foroni L; Godfrey AL; Gerrard G; Akiki S; Awan A; Carter I; Goday-Fernandez A; Langabeer SE; Clench T; Clark J; Evans PA; Grimwade D; Schuh A; McMullin MF; Green AR; Harrison CN; Cross NC;
Br J Haematol; 2013 Jan; 160(1):25-34. PubMed ID: 23057517
[TBL] [Abstract][Full Text] [Related]
5. Diagnostic value of JAK2 V617F somatic mutation for myeloproliferative cancer in 49 488 individuals from the general population.
Nielsen C; Birgens HS; Nordestgaard BG; Bojesen SE
Br J Haematol; 2013 Jan; 160(1):70-9. PubMed ID: 23116358
[TBL] [Abstract][Full Text] [Related]
6. High Risk Janus Kinase 2 V617F Allele Burden in a Seven-Year Cohort of Patients with Myeloproliferative Neoplasms.
Chatambudza M; Skhosana L; Ketseoglou I; Wiggill T
Clin Lab; 2021 Nov; 67(11):. PubMed ID: 34758219
[TBL] [Abstract][Full Text] [Related]
7. Low
Makarik TV; Abdullaev AO; Nikulina EE; Treglazova SA; Stepanova EE; Subortseva IN; Kovrigina AM; Melikyan AL; Kulikov SM; Sudarikov AB
Genes (Basel); 2021 Apr; 12(4):. PubMed ID: 33921387
[No Abstract] [Full Text] [Related]
8. Clinical Implications of Quantitative JAK2 V617F Analysis using Droplet Digital PCR in Myeloproliferative Neoplasms.
Lee E; Lee KJ; Park H; Chung JY; Lee MN; Chang MH; Yoo J; Lee H; Kong SY; Eom HS
Ann Lab Med; 2018 Mar; 38(2):147-154. PubMed ID: 29214759
[TBL] [Abstract][Full Text] [Related]
9. Analysis of JAK2V617F mutation in Jordanian patients with myeloproliferative neoplasms.
Jaradat SA; Khasawneh R; Kamal N; Matalka I; Al-Bishtawi M; Al-Sweedan S; Ayesh MH
Hematol Oncol Stem Cell Ther; 2015 Dec; 8(4):160-6. PubMed ID: 26256826
[TBL] [Abstract][Full Text] [Related]
10. JAK2 V617F mutation can be reliably detected in serum using droplet digital PCR.
Nystrand CF; Ghanima W; Waage A; Jonassen CM
Int J Lab Hematol; 2018 Apr; 40(2):181-186. PubMed ID: 29150911
[TBL] [Abstract][Full Text] [Related]
11. Association between thromboembolic events and the JAK2 V617F mutation in myeloproliferative neoplasms.
Takata Y; Seki R; Kanajii T; Nohara M; Koteda S; Kawaguchi K; Nomura K; Nakamura T; Morishige S; Oku E; Osaki K; Hashiguchi E; Mouri F; Yoshimoto K; Nagafuji K; Okamura T
Kurume Med J; 2014; 60(3-4):89-97. PubMed ID: 24858412
[TBL] [Abstract][Full Text] [Related]
12. JAK2 (V617F) as an acquired somatic mutation and a secondary genetic event associated with disease progression in familial myeloproliferative disorders.
Rumi E; Passamonti F; Pietra D; Della Porta MG; Arcaini L; Boggi S; Elena C; Boveri E; Pascutto C; Lazzarino M; Cazzola M
Cancer; 2006 Nov; 107(9):2206-11. PubMed ID: 16998940
[TBL] [Abstract][Full Text] [Related]
13. Changing concepts of diagnostic criteria of myeloproliferative disorders and the molecular etiology and classification of myeloproliferative neoplasms: from Dameshek 1950 to Vainchenker 2005 and beyond.
Michiels JJ; Berneman Z; Schroyens W; De Raeve H
Acta Haematol; 2015; 133(1):36-51. PubMed ID: 25116092
[TBL] [Abstract][Full Text] [Related]
14. A simple, rapid, and sensitive method for the detection of the JAK2 V617F mutation.
Tan AY; Westerman DA; Dobrovic A
Am J Clin Pathol; 2007 Jun; 127(6):977-81. PubMed ID: 17509995
[TBL] [Abstract][Full Text] [Related]
15. Detection of acquired Janus kinase 2 V617F mutation in myeloproliferative disorders by fluorescence melting curve analysis.
Reading NS; Lim MS; Elenitoba-Johnson KS
Mol Diagn Ther; 2006; 10(5):311-7. PubMed ID: 17022694
[TBL] [Abstract][Full Text] [Related]
16. A comparison of qPCR and ddPCR used for quantification of the JAK2 V617F allele burden in Ph negative MPNs.
Link-Lenczowska D; Pallisgaard N; Cordua S; Zawada M; Czekalska S; Krochmalczyk D; Kanduła Z; Sacha T
Ann Hematol; 2018 Dec; 97(12):2299-2308. PubMed ID: 30056580
[TBL] [Abstract][Full Text] [Related]
17. JAK2 46/1 haplotype is associated with JAK2 V617F--positive myeloproliferative neoplasms in Brazilian patients.
Macedo LC; Santos BC; Pagliarini-e-Silva S; Pagnano KB; Rodrigues C; Quintero FC; Ferreira ME; Baraldi EC; Ambrosio-Albuquerque EP; Sell AM; Visentainer JE
Int J Lab Hematol; 2015 Oct; 37(5):654-60. PubMed ID: 25959311
[TBL] [Abstract][Full Text] [Related]
18. JAK2 V617F Mutation and Large Cerebral Artery Disease in Patients with Myeloproliferative Neoplasms.
Oyama N; Iwamoto T; Doyu K; Miyazato S; Okazaki T; Yamada S; Kondo T; Wada H; Yagita Y
J Atheroscler Thromb; 2023 Dec; 30(12):1917-1926. PubMed ID: 37344447
[TBL] [Abstract][Full Text] [Related]
19. Detection of the JAK2 mutation in myeloproliferative neoplasms by asymmetric PCR with unlabeled probe and high-resolution melt analysis.
Cao HC; Lin J; Qian J; Yao DM; Li Y; Yang J; Chen Q; Chai HY; Xiao GF
J Clin Lab Anal; 2011; 25(4):300-4. PubMed ID: 21786333
[TBL] [Abstract][Full Text] [Related]
20. JAK2 V617F mutation prevalence in myeloproliferative neoplasms in Pernambuco, Brazil.
da Silva RR; Domingues Hatzlhofer BL; Machado CG; Lima AS; de Albuquerque DM; dos Santos MN; Fertrin KY; Costa FF; Araújo Ada S; Bezerra MA
Genet Test Mol Biomarkers; 2012 Jul; 16(7):802-5. PubMed ID: 22304488
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]